CKD Bio Corp. (KRX:063160)

Market Cap	126.18B
Revenue (ttm)	159.93B
Net Income (ttm)	-23.13B
Shares Out	5.49M
EPS (ttm)	-4,216.38
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.44%)
Ex-Dividend Date	Dec 27, 2024

Volume	13,354
Average Volume	7,622
Open	22,900
Previous Close	22,850
Day's Range	22,700 - 23,150
52-Week Range	19,710 - 35,700
Beta	1.34
RSI	56.60
Earnings Date	May 15, 2025

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 519
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 063160

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.